Mass spectrometry analysis of the influenza virus

Mass Spectrometry Reviews

Volumn 28, Issue 1, 2009, Pages 35-49

  Downard, Kevin M ^a   Morrissey, Bethny ^a   Schwahn, Alexander B ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Antigenicity; Antivirals; Flu; Hemagglutinin; Immunoassay; Influenza; Mass spectrometry; Surveillance; Virus

Indexed keywords

ANTIGENS; BODY FLUIDS; IMMUNOLOGY; MASS SPECTROMETERS; MASS SPECTROMETRY; SPECTROMETERS; SPECTROMETRY; SPECTRUM ANALYSIS; SURFACE STRUCTURE; VIRUSES;

ANTIGENICITY; ANTIVIRALS; FLU; HEMAGGLUTININ; IMMUNOASSAY; INFLUENZA; SURVEILLANCE; VIRUS;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ANTIVIRUS AGENT; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIGEN;

CHEMISTRY; GROWTH, DEVELOPMENT AND AGING; HUMAN; IMMUNOASSAY; IMMUNOLOGY; MASS SPECTROMETRY; METHODOLOGY; ORTHOMYXOVIRUS; ORTHOMYXOVIRUS INFECTION; PEPTIDE MAPPING; REVIEW; VIROLOGY; VIRUS REPLICATION;

ANTIGENS, VIRAL; ANTIVIRAL AGENTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; IMMUNOASSAY; INFLUENZA VACCINES; MASS SPECTROMETRY; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PEPTIDE MAPPING; VIRUS REPLICATION;

EID: 59149100139     PISSN: 02777037     EISSN: None     Source Type: Journal    
DOI: 10.1002/mas.20194     Document Type: Article

References (63)

1. Anhalt JP, Fenselau C. 1975. Identification of bacteria using mass spectrometry. Anal Chem 47:219-225.
2. Arndt T, Guessregen B, Hohl A, Reisb J. 2005. Determination of serum amantadine by liquid chromatography-tandem mass spectrometry. Clin Chim Acta 359:125-131.
3. Arnold RJ, Karty JA, Ellington AD, Reilly JP. 1999. Monitoring the growth of a bacteria culture by MALDI-MS of whole cells. Anal Chem 71:1990-1996.
4. Australian Bureau of Statistics. 2006. Causes of death in Australia in 2006. Publication 3303.0. Australian Bureau of Statistics, Canberra, Australia.
5. Barry JM. 2004. The great influenza: The epic story of the deadliest plague in history. New York, U.S.A.: Penguin Viking.
6. Baughman TM, Wright WL, Hutton KA. 2007. Determination of zanamivir in rat and monkey plasma by positive ion hydrophilic interaction chromatography (HILIC)/tandem mass spectrometry. J Chromatogr B 852:505-511.
7. Bothner B, Siuzdak G. 2004. Electrospray ionization of a whole virus: Analyzing mass, structure, and viability. ChemBioChem 5:258-260.
8. Carrat F, Flahault A. 2007. Influenza vaccine: The challenge of antigenic drift. Vaccine 25:6852-6862.
9. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. 1982. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 31:417-427.
10. Downard KM, Morrissey B. 2007. Fingerprinting a killer: Surveillance of the influenza virus by mass spectrometry. Analyst 132:611-614.
11. Fenselau C, Demirev PA. 2001. Characterization of intact microorganisms by MALDI mass spectrometry. Mass Spectrom Rev 20:157-171.
12. Gamblin SJ, Haire LF, Russell RJ, Stevens DJ, Xiao B, Ha Y, Vasisht N, Steinhauer DA, Daniels RS, Elliot A, Wiley DC, Skehel JJ. 2004. The structure and receptor binding properties of the 1918 influenza hemagglutinin. Science 303:1838-1842.
13. Garman E, Laver G. 2004. Controlling influenza by inhibiting the virus's neuraminidase. Curr Drug Targets 5:119-136.
14. Girard MP, Cherian T, Pervikov Y, Kieny MP. 2005. A review of vaccine research and development: Human acute respiratory infections. Vaccine 23:5708-5724.
15. Gorman JJ, Corino GL, Shiell BJ. 1990. Role of mass spectrometry in mapping strain variation and post-translational modifications of viral proteins. Biomed Environ Mass Spectrom 19:646-654.
16. Grunert RR, McGahen JW, Davies WL. 1965. The in vivo antiviral activity of 1-adamantanamine (amantadine). 1. Prophylactic and therapeutic activity against influenza viruses. Virology 26:262-269.
17. Heller DN, Cotter RJ, Fenselau C. 1987. Profiling of bacteria by fast atom bombardment mass spectrometry. Anal Chem 59:2806-2809.
18. Ho JWK, Morrissey B, Downard KM. 2007. A computer algorithm for the identification of protein interactions from the spectra of masses (PRISM). J Am Soc Mass Spectrom 18:563-566.
19. Horimoto T, Kawaoka Y. 2005. Influenza: Lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol 3:591-600.
20. Julkunen I, Pyhala R, Hovi T. 1985. Enzyme immunoassay, complement fixation and hemagglutination inhibition tests in the diagnosis of influenza A and B virus infections. Purified hemagglutinin in subtype-specific diagnosis. J Virol Methods 10:75-84.
21. Kattenhorn LM, Mills R, Wagner M, Lomsadze A, Makeev V, Borodovsky M, Ploegh HL, Kessler BM. 2004. Identification of proteins associated with murine cytomegalovirus virions. J Virol 78:.11187-11197.
22. Kawaoka Y, Krauss S, Webster RG. 1989. Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J Virol 63:4603-4608.
23. Kiselar JG, Downard KM. 1999a. Direct identification of protein epitopes by mass spectrometry without immobilization of antibody and isolation of antibody-peptide complexes. Anal Chem 71:1792-1799.
24. Kiselar JG, Downard KM. 1999b. Antigenic surveillance of the influenza virus by mass spectrometry. Biochemistry 38:14185-14191.
25. Kiselar JG, Downard KM. 2000. Preservation and detection of specific antibody-peptide complexes by matrix-assisted laser desorption ionization mass spectrometry. J Am Soc Mass Spectrom 11:746-750.
26. Kodihalli S, Justewicz DM, Gubareva LV, Webster RG. 1995. Selection of a single amino acid substitution in the hemagglutinin molecule by chicken eggs can render influenza A virus (H3) candidate vaccine ineffective. J Virol 69:4888-4897.
27. Krokhin O, Li Y, Andonov A, Feldman H, Flick R, Jones S, Stroeher U, Bastien N, Dasuri KVN, Cheng K, Simonsen JN, Perreault H, Wilkins J, Ens W, Plummer F, Standing KG. 2003. Mass spectrometric characterization of proteins from the SARS virus: A preliminary report. Mol Cell Proteomics 2:346-356.
28. Lanman J, Prevelige PE, Jr. 2005. Kinetic and mass spectrometry-based investigation of human immunodeficiency virus type 1 assembly and maturation. Adv Virus Res 64:285-309.
29. Laver WG, Bischofberger N, Webster RG. 1999. Disarming flu viruses. Sci Am 280:78-87.
30. Laver WG, Bischofberger N, Webster RG. 2000. The origin and control of pandemic influenza. Perspect Biol Med 43:173-192.
31. Lewis JK, Bendahmane M, Smith TJ, Beachy RN, Siuzdak G. 1998. Identification of viral mutants by mass spectrometry. Proc Natl Acad Sci USA 95:8596-8601.
32. Lewis JK, Chiang J, Siuzdak. G. 1999. Monitoring protein-drug interactions with mass spectrometry and proteolysis protein mass mapping as a drug assay. J Assoc Lab Automation 4:46-48.
33. Macken C, Lu H, Goodman J, Boykin L. 2001. The value of a database in surveillance and vaccine selection. In: Osterhaus ADME, Cox N, Hampson AW, editors. Options for the control of influenza IV. Amsterdam, Netherlands: Elsevier Science, p 103.
34. Mackun K, Downard KM. 2003. Strategy for identifying protein-protein interactions of gel-separated proteins and complexes by mass spectrometry. Anal Biochem 318:60-70.
35. Morton VL, Stockley PG, Stonehouse NJ, Ashcroft AE. 2008. Insights into virus capsid assembly from non-covalent mass spectrometry. Mass Spectrom Rev (in press).
36. Morrissey B, Downard KM. 2006. A proteomics approach to survey the antigenicity of the influenza virus by mass spectrometry. Proteomics 6:2034-2041.
37. Morrissey B, Streamer M, Downard KM. 2007. Antigenic characterisation of H3N2 subtypes of the influenza virus by mass spectrometry. J Virol Methods 145:106-114.
38. Muddiman DC, Anderson GA, Hofstadler SA, Smith RD. 1997. Length and base composition of PCR-amplified nucleic acids using mass measurements from electrospray ionization mass spectrometry. Anal Chem 69:1543-1549.
39. Murray S, Nilsson CL, Hare JT, Emmett MR, Korostelev A, Ongley H, Marshall AG, Chapman MS. 2006. Characterization of the capsid protein glycosylation of adeno-associated virus type 2 by high-resolution mass spectrometry. J Virol 80:6171-6176.
40. Neumayer EM, Haff RF, Hoffman CE. 1965. Antiviral activity of amantadine hydrochloride in tissue culture and in ovo. Proc Soc Exp Biol Med 19:393-396.
41. Nicholson KG, Wood JM, Zambon M. 2003. Influenza. Lancet 362:1733-1745.
42. O'Connell J, editor. 2002. RT-PCR Protocols. Methods in Molecular Biology Vol. 193. New Jersey, U.S.A.: Humana Press, p 378.
43. Pappin DJC, Hojrup P, Bleasby AJ. 1993. Rapid identification of proteins by peptide-mass fingerprinting. Curr Biol 3:327-332.
44. Reid AH, Taubenberger JK. 2003. The origin of the 1918 pandemic influenza virus: A continuing enigma. J Gen Virol 84:2285-2292.
45. Sampath R, Russell KL, Massire C, Eshoo MW, Harpin V, Blyn LB, Melton R, Ivy C, Pennella T, Li. F, Levene H, Hall TA, Libby B, Fan N, Walcott DJ, Ranken R, Pear M, Schink A, Gutierrez J, Drader J, Moore D, Metzgar D, Addington L, Rothman R, Gaydos CA, Yang S, St George K, Fuschino ME, Dean AB, Stallknecht DE, Goekjian G, Yingst S, Monteville M, Saad MD, Whitehouse CA, Baldwin C, Rudnick KH, Hofstadler SA, Lemon SM, Ecker DJ. 2007a. Global surveillance of emerging Influenza virus genotypes by mass spectrometry. PLoS ONE 2:e489.
46. Sampath R, Hall TA, Massire C, Li F, Blyn LB, Eshoo MW, Hofstadler SA, Ecker DJ. 2007b. Rapid identification of emerging infectious agents using PCR and electrospray ionization mass spectrometry. Ann NY Acad Sci 1102:109-120.
47. Schwahn AB, Downard KM. 2008. Antigenicity of a type A influenza virus through a comparison of hemagglutinin inhibition and mass spectrometry immunoassays, (submitted for publication).
48. Serebryakova MV, Kordyukova LV, Baratova LA. 2006. Mass spectrometric sequencing and acylation character analysis of C-terminal anchoring segment from Influenza A hemagglutinin. Eur J Mass Spectrom 12: 51-62.
49. Sheshberadaran H, Payne LG. 1988. Protein antigen-monoclonal antibody contact sites investigated by limited proteolysis of monoclonal antibody-bound antigen: Protein footprinting. Proc Natl Acad Sci USA 85:1-5.
50. Smith JP, Riley TR III, Bingaman S, Mauger DT. 2004. Amantadine therapy for chronic hepatitis C: A dose escalation study. Am J Gastroenterol 99: 1099-1104.
51. Siuzdak G. 1998. Probing viruses with mass spectrometry. J Mass Spectrom 33:203-211.
52. Subbarao K, Klimov A, Katz J, Regnery H, Lim W, Hall H, Perdue M, Swayne D, Bender C, Huang J, Hemphill M, Rowe T, Shaw M, Xu X, Fukuda F, Cox N. 1998. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fetal respiratory illness. Science 279:393-396.
53. Swatkoski S, Russell S, Edwards N, Fenselau C. 2007. Analysis of a model virus using residue-specific chemical cleavage and MALDI-TOF mass spectrometry. Anal Chem 79:654-658.
54. Sweeny DJ, Lynch G, Bidgood AM, Lew W, Wang KY, Cundy KC. 2000. Metabolism of the influenza neuraminidase inhibitor prodrug oseltamivir in the rat. Drug Metab Dispos 28:737-741.
55. Stephenson I, Nicholson KG. 2001. Influenza: Vaccination and treatment. Eur Respir J 17:1282-1293.
56. Trauger AS, Junker T, Siuzdak G. 2003. Investigating viral proteins and intact viruses with mass spectrometry. Top Curr Chem 225:265-282.
57. Webster RG, Walker EJ. 2003. Influenza: The world is teetering on the edge of a pandemic that could kill a large fraction of the human population. Am Sci 91:122.
58. Williams TL, Luna L, Guo Z, Cox NJ, Pirkle JL, Donis RO, Barr JR. 2008. Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. Vaccine 26:2510-2520.
59. Wilkins MR, Williams KL, Appel RL, Hochstrasser DF, editors. 1997. Proteome Research: New Frontiers in Functional Genomics (Principles and Practice). Berlin: Springer Verlag.
60. Wiltshire H, Wiltshire B, Citron A, Clarke T, Serpe C, Gray D, Herron W. 2000. Development of a high-performance liquid chromatographicmass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine. J Chromatogr B Biomed Sci Appl 745:373-388.
61. Wright KE, Wilson GA, Novosad D, Dimock C, Tan T, Weber JM. 1995. Typing and subtyping of influenza viruses in clinical samples by PCR. J Clin Microbiol 33:1180-1184.
62. Wood JM. 2002. Selection of influenza vaccine strains and developing pandemic vaccines. Vaccine 20 (Suppl 5):B40-B44.
63. Yao ZP, Demirev PA, Fenselau C. 2002. Mass spectrometry-based proteolytic mapping for rapid virus identification. Anal Chem 74:2529-2534.